CardioKinetix has developed a novel transcatheter implant called the Parachute Ventricular Partitioning Device (Parachute). The Parachute is designed to be a catheter-based partitioning device deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. The Parachute implant partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, which decreases the overall volume and restores a more normal geometry and function in the left ventricle.

Company Growth (employees)
Menlo Park, US
Size (employees)
28 (est)-15%
CardioKinetix was founded in 2003 and is headquartered in Menlo Park, US

Key People/Management at CardioKinetix

Maria Sainz

Maria Sainz

President & CEO & Board Director
Brett Hale

Brett Hale

Bob Nicholas

Bob Nicholas

VP, Operations

CardioKinetix Office Locations

CardioKinetix has an office in Menlo Park
Menlo Park, US (HQ)
1360 O'Brien Dr

CardioKinetix Financials and Metrics

Summary Metrics

CardioKinetix's latest funding round in December 2014 was reported to be $50 m. In total, CardioKinetix has raised $135.5 m

CardioKinetix's Web-traffic and Trends

CardioKinetix Company Life and Culture

You may also be interested in